Nymirum is a venture-backed, privately held drug discovery company that has developed a proprietary technology platform that targets RNA with small molecules.
Drug developers around the world have focused on RNA as one of the most promising new areas of the 21st century. Utilizing small molecules avoids the drug delivery difficulties inherent in nucleic acid-based approaches and enables orally available treatments for a broad range of diseases.
Nymirum's platform is both complimentary and disruptive. Our platform was specifically built to fit within the industry's existing infrastructure, providing new molecules and scaffolds for newly validated RNA targets which are fed into the traditional med chem and biology pipeline. We enable the industry to attack a new generation of higher-probability targets rather than continuing to solely focus on the same protein targets that have been worked on for generations with diminishing returns.
In addition to our own internal drug discovery programs, Nymirum has formed development partnerships with Fortune 500 pharmaceutical and medical companies.